5-Fluorouracil-loaded BSA nanoparticles: Formulation optimization and in vitro release study

AAPS PharmSciTech

Volumn 9, Issue 4, 2008, Pages 1092-1096

  Maghsoudi, Amir ^a   Shojaosadati, Seyed Abbas ^a   Vasheghani Farahani, Ebrahim ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

5 fluorouracil; BSA; Drug release; Nanoparticle; Optimization

Indexed keywords

ALCOHOL; BOVINE SERUM ALBUMIN; FLUOROURACIL; GLUTARALDEHYDE; NANOPARTICLE;

ANTIGENICITY; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; MOLECULAR WEIGHT; PARTICLE SIZE; PROCESS OPTIMIZATION; SUSPENSION; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; CHEMISTRY; IN VITRO STUDY; PH;

FLUOROURACIL; GLUTARAL; HYDROGEN-ION CONCENTRATION; NANOPARTICLES; SERUM ALBUMIN, BOVINE;

EID: 63649131445     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9146-5     Document Type: Article

References (24)

1. F. DeJaeghere, E. Doelker, and R. Gurny. Nanoparticles. In E. Mathiowitz (ed.), Encyclopedia of Controlled Drug Delivery, Wiley, Hoboken, 1999, pp. 641-664.
2. S. M. Moghimi, A. C. Hunter, and J. C. Murray. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53:283-318 (2001).
3. B. G. Muller, H. Leuenberger, and T. Kissel. Albumin nanospheres as carriers for passive drug targeting: An optimized manufacturing technique. Pharm. Res. 13: 32-37 (1996).
4. G. V. Patil. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev. Res. 58:219-247 (2003).
5. M. Michaelis, K. Langer, S. Arnold, H. Doerr, J. Kreuter, and J. Cinatl. Pharmacological activity of DTPA linked to protein-based drug carrier systems. Biochem. Bioph. Res. Co. 323:1236-1240 (2004).
6. C. Weber, C. Coester, J. Kreuter, and K. Langer. Desolvation process and surface characterization of protein nanoparticles. Int. J. Pharm. 194:91-102 (2000).
7. M. Merodio, A. Arnedo, M. J. Renedo, and J. M. Irache. Ganciclovir-loaded albumin nanoparticles: Characterization and in vitro release properties. Eur. J. Pharm. Sci. 12:251-259 (2001).
8. M. Merodio, J. M. Irache, F. Valamanesh, and M. Mirshahi. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials. 23:1587-1594 (2002).
9. W. Lin, M. C. Garnett, S. S. Davis, E. Schacht, P. Ferruti, and L. Illum. Preparation and characterization of rose Bengal-loaded surface-modified albumin nanoparticles. J. Control. Rel. 71:117-126 (2001).
10. S. S. D'Souza, and P. P. DeLuca. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm. Res. 23:460-474 (2006).
11. S. S. D'Souza, and P. P. DeLuca. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech. 62:E323-E328 (2005).
12. J. W. Kostanski, and P. P. DeLuca. A novel in vitro release technique for peptide-containing biodegradable microspheres. AAPS PharmSciTech. 11:4 (2000).
13. M. Boisdron-Celle, P. Menei, and J. P. Benoit. Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J. Pharm. Pharmacol. 47:108-114 (1995).
14. N. Faisant, J. Siepmann, and J. P. Benoit. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci. 15:355-366 (2002).
15. A. Bozkir, and O. M. Saka. Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. Il Farmaco. 60:840-846 (2005).
16. Y. Zheng, W. Yang, C. Wang, J. Hu, S. Fu, L. Dong, L. Wu, and X. Shen. Nanoparticles based on the complex of chitosan and polyaspartic acid sodium salt: Preparation, characterization and the use for 5-fluorouracil delivery. Eur. J. Pharm. Biopharm. 67:621-631 (2007).
17. L. Liu, P. Jin, M. Cheng, G. Zhang, and F. Zhang. 5-fluorouracil-loaded self-assembled pH-sensitive nanoparticles as novel drug carrier for treatment of malignant tumors. Chin. J. Chem. Eng. 14:377-382 (2006).
18. S. Li, A. Wang, W. Jiang, and Z. Guan. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer. 8:103 (2008).
19. P. A. McCarron, A. D. Woolfson, and S. M. Keating. Sustained release of 5-fluorouracil from polymeric nanoparticles. J. Pharm. Pharmacol. 52:1451-1459 (2000).
20. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima. Microsphere design for the colonic delivery of 5-fluorouracil. J. Control. Rel. 90:313-322 (2003).
21. K. Santhi, S. A. Dhanaraj, V. Joseph, S. Ponnusankar, and B. Suresh. A study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5-fluorouracil. Drug Dev. Ind. Pharm. 28:1171-1179 (2002).
22. C. Lo, K. Lin, and G. Hsiue. Preparation and characterization of intelligent core-shell nanoparticles based on poly(d, l-lactide)-g-poly(N-isopropyl acrylamide-co-methacrylic acid). J. Control. Rel. 104:477-488 (2005).
23. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, and D. Schubert. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257:169-180 (2003).
24. R. K. Roy. A Primer on the Taguchi Method, Van Nostrand Reinhold, New York, 1990.